drugset
drugset / Trial / NCT05911048

A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination

NCT05911048 ↗

Phase 2 Not yet recruiting 3100 enrolled WestVac Biopharma Co., Ltd.
RandomizedParallel-groupDouble-blindPrevention

Summary

A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination to evaluate safety and immunogenicity in healthy population aged 18 years old and above.

Timeline

Start
2024-12-30
Primary completion
2025-06-30
Completion
2025-12-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator WSK-V101 Vaccine — —
Subject WSK-V101C Vaccine — —

Indications

COVID-19